# MapLight shares sink on mixed ph. 2 schizophrenia readout

> **Newsylist Open Intelligence Dossier** · First detected: 2026-07-27 23:29 UTC · Category: Business · Sources: 7 · Current Velocity: 4.63

## Executive Summary
7 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

## Intelligence Brief
"MapLight shares sink on mixed ph. 2 schizophrenia readout" is generating significant coverage in the Business category, with 7 articles from 7 distinct sources tracked by Newsylist so far.


Outlets currently covering the story include BioWorld News, Yahoo Finance, BioPharma Dive and Investing.com. Newsylist measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.

## Verified Facts & Key Claims
### Why is "MapLight shares sink on mixed ph. 2 schizophrenia readout" trending?
Because 7 independent news sources published 7 articles about it in a short window — a coverage burst Newsylist classifies as a trend.

### How does Newsylist measure this trend?
Newsylist scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.

### Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.

## Key People, Organizations & Locations
Phase, Maplight, MapLight Therapeutics, TD Cowen, Biotech And AI Stocks Got Hit On Mixed News, Topline Results From ZEPHYR Trial ML-007C-MA for the Treatment of Schizophrenia, MPLT Stock Plunges, Wipes Out Over, In Market Cap After Trial Miss On Once-Daily Dose

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| BioWorld News | Maplight aims to differentiate muscarinic agonist from competitors | 2026-07-27 15:37 | [Source Link](https://news.google.com/rss/articles/CBMiqwFBVV95cUxOaUh2OHNidG8tUjA0UDA2a2tlZGluRjhEOWRsY1NMaEU4UnJtOEFZUVViSnl6djRZc0cxMHlPS21pcGZiZFZTZkVZMlhNenA3V05CcnVRWnVENzhDQ3cxV2lQeW9sMTRiOGd4dXRVb2R1QjRVZmhZelZQYzdJajA1cGljX05KQ1hGdm5HNmNoeEJzSDdQMmpDa2ZtbjR1Z01FRm8yWWlJZzIxNW8?oc=5) |
| Yahoo Finance | MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose | 2026-07-27 15:37 | [Source Link](https://news.google.com/rss/articles/CBMikgFBVV95cUxQcEh2TDJnaHpSUG5uanUtRWFFa3F4MnVVc0xhclJqY1pJcXdFNzFrcmRlMGxvVVJlNW9UaU9MRFpzNV9xWVVvMFpYMWZtVkFCQlVvdU5RUE93S2hMQjNGTHRBVHpKZDA0N3dKWlA2aFZnV1k1dHlXWFQ5b3F3ZFhQNTI5QS1GTTNNTkt1cHRBX3JhUQ?oc=5) |
| BioPharma Dive | MapLight dives despite positive data for schizophrenia drug | 2026-07-27 15:37 | [Source Link](https://news.google.com/rss/articles/CBMinwFBVV95cUxPejBoV244TnByVEc2SUpaRFF3MzlmZkU4elNYMUluTDh0OEJLc1RUWUhUTGg1SlBHVUdSYVJ1ZVFpbGxfUkljNkhkM3RFM1dRZFZMMlA0UWJVRTY2N0hHT29yVmpyNEhRcHdJWTRJVDUzaFpyaXpVcG15RFlBTHVJYUJMekRaaVBObGFoRXI0Q3ZkOTRuVk84YnBhaVdwZ28?oc=5) |
| Investing.com | MapLight Therapeutics stock holds Buy rating at TD Cowen after trial data | 2026-07-27 15:37 | [Source Link](https://news.google.com/rss/articles/CBMizgFBVV95cUxNUm5NUjRGMm1jUUZWWHFsb0RRZHJSRldnZm5fcXlmYlVycVpEQmpidGlnUnVVRlR3U0tTejZvMUJyLUt5d3lMdXppaVgxVXRTWHMtQVRoS3p0MElwMXVCWERsMFdZX0c2eFFhM0pSS2dxRk9YUXA0TzNDRkZXOGdwTnBvS3I1X0VtTTN0LW40bFdYTlBEMV9QQmZIemRMeWlwdHphakhDUmF4RkFlNDN1b2tkWlVBN202enRGeThYOGVrbHJJVmVvdjBOWWZmdw?oc=5) |
| Finimize | Biotech And AI Stocks Got Hit On Mixed News | 2026-07-27 15:37 | [Source Link](https://news.google.com/rss/articles/CBMifEFVX3lxTFBCTXNiZzBZRzJ3TWRIUkxVelZFalZXUkYwMlN1NzRfYVJ3WVhXVDRVYTlyOTZkeENjdnVLN3VqSjEzZ2dfZGFkOHp3VGwxNHlUUHdhSEtZaS1kSk85bnp0SGMwTWlDcHZNTWpnMXczYkRNQmJfYXVqRDlxQWI?oc=5) |
| Psychiatric Times | Phase 2 Topline Results From ZEPHYR Trial: ML-007C-MA for the Treatment of Schizophrenia | 2026-07-27 15:37 | [Source Link](https://news.google.com/rss/articles/CBMiwwFBVV95cUxNaURoamR5VU5nbW5CM0VrVFYyUW85MzhRVjBzRHRTeldRbGRTX292MS1kZFJlWmlRaWQwZ3d3Vm85MlFBM2dnZ3BLLWZabTBkR2hVNnh1RVhPY1R5b2tuTlJzUlJBeThJVlRBMWdDclNGSFNDcG55S1VVVUFwUi1Oai0xUmZFeUk4M3VpOGgzTzRSTzg3STZDVU56c2FVZWRMUTZzclRPb3lQQzRtaDNUUXdkNEUydEdFd25RVWVLY0VDeUk?oc=5) |
| Fierce Biotech | MapLight shares sink on mixed ph. 2 schizophrenia readout | 2026-07-27 15:37 | [Source Link](https://news.google.com/rss/articles/CBMilgFBVV95cUxNaGRCajhpNlhOdEFyNlFsdWN6T1Y0YzZaQUZseXE2c0dyVzdmR05sbVRSTHRKYjQ1WHdNYWtHaUpIMFJrX24yaVp2VTVhV3N5N1dwLVBqQUlYVFpQOEQ4UUFzSkt4dzhaWkx6bGN2a2xONmdaMmMxanQxRGpESWkwQ1lBZ0haWUxJT0lEMXFNWU1LM0ZXeVE?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-07-27/maplight-shares-sink-on-mixed-ph-2-schizophrenia-readout*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*